The FDA order permitting bemotrizinol in American sunscreens takes effect on Sunday, August 9. Shoppers hoping to find it on a shelf that week will not.
The date marks the moment the ingredient may legally be marketed in the United States, the first new active added to the over-the-counter sunscreen monograph since the late 1990s. It is a production milestone, not a retail one, and the gap between the two is where most consumer confusion is going to sit for the rest of this summer.
For anyone shopping for sun protection in August, the practical answer is unchanged. The sunscreen that works is the one already on the shelf, applied correctly and reapplied.
The Order Permits Marketing, Not Immediate Sale
The FDA issued Final Administrative Order OTC000039 in June, adding bemotrizinol to the list of permitted active ingredients under sunscreen monograph M020. MedicalDaily reported at the time on the approval and what the ingredient does.
The order was initiated by a Tier 1 monograph order request submitted by DSM Nutritional Products in September 2024, followed by a proposed order in December 2025 and a comment period that drew roughly 50 comments. Analysis by the law firm Venable notes it is the first active ingredient added to any over-the-counter monograph through the process created by the CARES Act of 2020, after the 2014 Sunscreen Innovation Act failed to produce a single approval. DSM first applied to add the ingredient in 2005, and that request sat for nearly two decades.
Two limits in the final order matter for shoppers. The FDA found the company's aerosol spray data insufficient, so the order covers non-aerosol forms rather than sprays. And DSM holds 18 months of exclusivity running from August 9.
That exclusivity is narrower than it sounds. The text of the final order extends marketing rights to DSM's licensees, assignees and successors, so companies that license the filter may sell products during the exclusivity period. Kenvue, the parent company of Neutrogena and Aveeno, has confirmed plans to incorporate bemotrizinol into US products. Broader availability across the market is expected once exclusivity ends in early 2028.
The Filter Covers a Range US Formulators Have Struggled With
Bemotrizinol, also sold internationally as Tinosorb S and marketed by DSM as PARSOL Shield, is an oil-soluble organic filter with high molecular weight. It absorbs across both the UVA and UVB range and is notably photostable, meaning it degrades slowly in sunlight rather than breaking down over the course of an afternoon.
That combination is what US formulators have lacked. Existing organic filters approved in the United States are weaker in the longer UVA range, and mineral filters such as zinc oxide and titanium dioxide provide good coverage but often leave a visible white cast.
The FDA determined the ingredient generally recognized as safe and effective at concentrations up to 6 percent in broad-spectrum products for adults and children 6 months and older, citing low absorption through skin. It has been used in Europe and Asia for years. Its addition brings the number of approved US sunscreen actives to 17, against more than 30 UV filters approved in the European Union, as one clinical summary noted.
The cosmetic consequence is not trivial. A filter that spreads easily and does not leave a chalky film is more likely to be applied generously and reapplied, and adherence is where most real-world sun protection is lost.
Shelf Timing Depends on Manufacturers, Not Regulators
Nothing about the August 9 date obligates any company to launch anything. Formulation, stability testing, SPF and broad-spectrum testing, packaging, labeling, and distribution each take months, which is why dermatologists tracking the rollout expect first products late this year at the earliest.
The reason the regulatory difference matters, as one legal analysis explains, is that the European Union treats sunscreen as a cosmetic while the FDA treats it as an over-the-counter drug, subject to a more demanding review.
When products do appear, the ingredient may be listed under several names. The active ingredients panel on a US-compliant label is the place to look, and the name most likely to appear there is bemotrizinol.
One caution for shoppers buying internationally: some Korean and European sunscreens contain the filter in their home market versions, but products formulated for US sale may carry different actives. An imported bottle is not regulated as a US over-the-counter drug, and its SPF claim has not been reviewed by the FDA.
Sun Protection Choices That Apply This Weekend
Skin cancer is the most commonly diagnosed cancer in the United States, and the protective behaviors that matter have not changed with this order.
Current guidance from dermatology organizations is broad-spectrum SPF 30 or higher, applied about 15 minutes before going outside, using roughly a shot glass worth for the exposed body, and reapplied every two hours or after swimming or heavy sweating. Shade, wide-brimmed hats, and UV protective clothing do work that no bottle does.
People with a history of skin cancer, a family history of melanoma, many moles, fair skin that burns easily, or who take photosensitizing medications including certain antibiotics, diuretics, and acne treatments should be more rigorous and should ask a dermatologist about a screening schedule. Anyone noticing a mole that changes in size, shape, or color, bleeds, or fails to heal should have it evaluated rather than waiting.
Cost is a real barrier, and the newest ingredient will not be the cheapest. Generic and store-brand broad-spectrum sunscreens meeting the same SPF and broad-spectrum standards are widely available at lower prices and work.
What happens next is a commercial question rather than a regulatory one. Watch for launch announcements from DSM and its licensees, and for the exclusivity period to lapse in early 2028, when other manufacturers may begin using the filter independently.
Frequently Asked Questions
Can I buy bemotrizinol sunscreen on August 9? No. That is the date the ingredient may legally be marketed. Finished products are expected to reach shelves later.
Why the delay between approval and availability? Formulation, stability and SPF testing, labeling and distribution take months. DSM also holds 18 months of exclusivity from August 9.
Does exclusivity block every other company? No. It extends to DSM's licensees, so licensed manufacturers may sell during that window. Kenvue has confirmed plans to use the ingredient.
Is it available in sprays? Not under this order. The FDA found the submitted aerosol data insufficient, so the approval covers non-aerosol forms.
Is it safe for children? The FDA determined it is generally recognized as safe and effective at up to 6 percent for adults and children 6 months and older.
Should I stop using my current sunscreen? No. Broad-spectrum SPF 30 or higher applied generously and reapplied every two hours remains effective protection.
Can I buy an imported version now? International products containing the filter exist, but they are not regulated as US over-the-counter drugs and their SPF claims have not been FDA reviewed.`
